OTLK – outlook therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note [Yahoo! Finance]
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Oncobiologics (OTLK) had its price target lowered by Ascendiant Capital Markets from $10.00 to $6.00. They now have a "buy" rating on the stock.
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) [Yahoo! Finance]
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Form 8-K Outlook Therapeutics, For: Mar 13
Form 8-K Outlook Therapeutics, For: Mar 06
Form 8-K Outlook Therapeutics, For: Mar 10
Form 8-K Outlook Therapeutics, For: Mar 05
Form 8-K Outlook Therapeutics, For: Feb 18
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.